title: A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia.
authors.affiliation: Furiex Pharmaceuticals, Inc., Morrisville, NC, USA.
authors.forename: Paul S
authors.initials: PS
authors.lastname: Covington
authors.forename: J Michael
authors.initials: JM
authors.lastname: Davenport
authors.forename: David A
authors.initials: DA
authors.lastname: Andrae
authors.forename: Martin E
authors.initials: ME
authors.lastname: Stryjewski
authors.forename: Lisa L
authors.initials: LL
authors.lastname: Turner
authors.forename: Gail
authors.initials: G
authors.lastname: McIntyre
authors.forename: June
authors.initials: J
authors.lastname: Almenoff
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001419:Bacteria / Q000145:classification / Q000302:isolation & purification; D017714:Community-Acquired Infections / Q000188:drug therapy*; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: C550935:7-(3-(2-amino-1-fluoroethylidene)-1-piperidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid; D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones
keywords: CABP; Streptococcus pneumoniae; respiratory pathogens